Inventiva (IVA) Receivables - Accured (2022 - 2023)
Inventiva (IVA) posted quarterly Receivables - Accured of $14.9 billion for Q2 2025, up 17367947.13% quarter-over-quarter from $86025.0 in Q2 2023.
Powered by 
Analysis
Inventiva (IVA) Receivables - Accured (2022 - 2023) Analysis & Trends
Inventiva's Receivables - Accured history runs 3 years deep, the most recent figure standing at $14.9 billion for Q2 2025.
- In Q2 2025, Receivables - Accured changed N/A year-over-year to $14.9 billion; the TTM figure through Jun 2025 stood at $14.9 billion (changed N/A YoY), while the FY2022 annual figure was $66316.1, changed N/A from the prior year.
- Receivables - Accured for Q2 2025 stood at $14.9 billion, up from $86025.0 in the prior quarter.
- The five-year high for Receivables - Accured was $14.9 billion in Q2 2025, with the low at $66316.1 in Q4 2022.
- The 3-year median for Receivables - Accured is $86025.0 (2023), against an average of $5.0 billion.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Inventiva | 893.85 Mn | 893.85 Mn | - | - |